Blood pressure may be especially important for young adults

July 29, 2008

There’s more to the risk of prehypertension than just the “pre” part

Prehypertension before age 35 is an independent risk factor for coronary calcification (a predictor of heart attacks and strokes), and not just because it so often leads to hypertension later. So says a large prospective study reported in Annals of Internal Medicine.

Subjects were between 18 and 30 at baseline and an average of 44 years old at follow-up.

A systolic pressure over 130 mmHg in a young adult raises the later risk of coronary calcium by 70%.

The results bolster the Joint National Commission guidelines for lifestyle modifications to reduce prehypertension.

You’ve seen a new report, and you have questions. SearchMedica can help you find the answers in a flash.

Related searches

prehypertension

systolic hypertension

coronary calcium

Patient education

Choose from a long list of authoritative, trustworthy resources for patients about how to manage their prehypertension without taking a medication.

Practical Articles/News

What expert advice can you find on the same topic?


New algorithm for depression treatment late in life

July 29, 2008

Early response trumps all in predicting antidepressant success in elderly

How do you know when a particular antidepressant is working in an elderly patient, or whether the treatment strategy should change? Merging results from three NIMH studies of geriatric depression, researchers have devised a decision tree to help assess the question. The report appears in the American Journal of Psychiatry.

In general, early symptom improvement after 4 weeks of treatment predicts antidepressant response in this population. Other decision factors include the age of onset, sleep disturbance, and the co-occurrence of anxiety disorder.

Elsewhere in the same issue, an MRI study reveals why mild cognitive impairment often subsides after remission of depression, while executive function may remain impaired. These results may also inform treatment decisions involving geriatric patients.

Related searches

Hamilton Depression Rating Scale

executive function depression elderly

Practice Guidelines

Find recent guidelines about diagnosing and managing depression in the elderly here.

Practical Articles/News

A search here reveals that impaired executive function is associated with suicide risk in the elderly.


Don’t blame her mood on her condition

July 22, 2008

New underserved population in psychiatry: Moms-to-be

Pregnancy per se is not associated with new or recurrent Axis I mental disorders, according to the first nationally representative sampling to address the question by comparing pregnant and non-pregnant women. And in general, pregnant women are less likely to abuse drugs or alcohol.

The exception was major depressive disorder, which was more prevalent among women who had given birth within the past year. (The study did not assess psychotic disorders.)

Pregnant women who did have psychiatric disorders were significantly less likely than other women to seek professional help (perhaps in part fearing medication risks to the fetus). The report in Archives of General Psychiatry suggests looking into barriers to care for this population group.

Related searches

pregnancy psychosis

psychopharmacology pregnancy risks fetus

Evidence-based Articles

Are there any proven non-drug interventions for postpartum depression?

Clinical Trials

What’s being tested now in clinical trials of postpartum depression?


Parents’ gut feelings seen as clues to monitoring asthma treatment

July 22, 2008

Pediatricians use clues beyond guidelines to adjust asthma regimens

Pediatricians may rely heavily on factors other than asthma symptoms in making their treatment decisions, according to a survey newly published in Pediatrics. The report says the survey was spurred by inappropriate treatment of asthma in children.

The survey presented 500 members of the American Academy of Pediatrics (most of them in suburban private practice) with vignettes of asthma cases.

Guidelines advise doctors to reduce treatment to the lowest levels that control symptoms. Respondents were significantly less likely to say they would step down treatment for a child with well-controlled symptoms if:
* parents said they were bothered by the symptoms,
* the child had recently been hospitalized, or
* symptoms were still in control, but worse since the last visit

None of this may be inappropriate, the report said. Perhaps doctors might like an “easy to use tool” that incorporates these factors.

In general, the survey suggests, most pediatricians now prescribe inhaled corticosteroids appropriately. Their long-term effects on bone density are not severe enough to justify limiting their use for children with asthma, according to another new report in Pediatrics.

Research/Reviews

Find reviews in this section on achieving asthma control.

Practice Guidelines

Quickly find the latest guidelines on management of asthma in children.

Related Searches

parents asthma

assess asthma symptoms

asthma overtreatment


Will pinprick replace lung biopsy for cancer tracking?

July 22, 2008

Beyond biopsy: Experimental blood test monitors NSCLC treatment

The Harvard/Mass General researchers who came up with a blood test that can monitor lung-cancer treatment have published their report in the New England Journal of Medicine.

The test uses a microchip that filters tumor cells bearing the carcinoma-specific epithelial cell adhesion molecule (EpCAM), and then scans them for EGFR mutations. In a 23-patient study, the noninvasive method genotyped tumor cells with 96% sensitivity. Presence of the drug-resistance mutation T790M, detectable in about 40% of patients, correlated with reductions in progression-free survival.

Detecting the evolution of resistance to receptor-targeted drugs would obviously avoid wasting time and money, not to mention human suffering, says an editorial. But whether the method will evolve into a clinically useful test remains to be seen.

Start with SearchMedica, and you can move quickly and easily to find relevant information on topics related to your original query.

Related Searches

EpCAM

T790M

Research Reviews

What’s the latest progress to monitor treatment by assaying circulating tumor cells in breast cancer?

CME

Remind yourself about EGFR mutations in lung cancer with an online course.


Treated in time, HIV no longer kills

July 15, 2008

Late treatment effects—not so much the virus—threaten new HIV patients

People diagnosed with sexually transmitted HIV in the industrialized world today have no greater risk of death within five years than the general population, according to the latest report from the multicenter European CASCADE study.

Those still at somewhat greater risk:

* Intravenous drug users
* People not treated immediately with the HAART regimen.
* In general, men compared with women.

Patients may yet face some excess mortality risk, starting a decade after they first show evidence of anti-HIV antibodies. This is probably due to the cardiac effects of the treatment regimen.

Related searches

CASCADE Collaboration HIV (Other results from the European study)

DAD study HIV (First evidence of heart risks from antiviral drugs)

SMART study HIV (Why restricting antivirals because of this risk is a bad idea)

CME

Find a free government-sponsored online CME course about HIV management.

Practice Guidelines

Find recent guidelines from the New York State Department of Health that address HIV management in primary care.

These guidelines give special attention to management of anxiety and depression, including increased risk of suicide, in this patient population.

Research/Reviews

Look to this category for more information about HAART toxicity.


Antipsychotics won’t stop a bully

July 15, 2008

Antipsychotics quell violence in schizophrenia–unless that’s not the cause

In general, antipsychotic medication leads to significant reductions in violent behavior among schizophrenia patients, according to new results from the multicenter CATIE study, sponsored by the National Institute of Mental Health.

However, look also for non-psychotic sources of violent behavior, suggests the report in the British Journal of Psychiatry, which medications will not help and which may require intensive therapy. For instance, among subjects with a childhood history of antisocial conduct problems, adherence to antipsychotic medication had no effect on the prevalence of violent behavior.

The 1445-patient study also revealed the following predictors of violent behavior among schizophrenia patients:

* Childhood conduct problems
* Substance misuse
* History of violent victimization
* Economic deprivation
* Living with others rather than alone

Schizophrenia patients with negative psychotic symptoms were less likely to be violent.

Related searches

victimization of mentally ill

MacArthur study

Practical Articles/News

A search here turns up an article from last month’s Psychiatric Times about how to protect yourself against a violent patient.

Research Reviews

Find studies on the effects of clozapine on violent patients with schizophrenia. (Clozapine was not included for patients in this arm of the CATIE study.)


For resistant depression: Rewire brain

July 8, 2008

Deep brain stimulation shows promise for treatment-resistant depression

Deep brain stimulation (DBS) is back in the news, after an Emory University speaker reviewed evidence for its efficacy in treatment-resistant depression at the APA meeting. Patients remain awake during the procedure, and some report an immediate lift.

The FDA has approved DBS for Parkinsonism and then for tremor caused by a number of neurologic disorders.

Investigators are trying the procedure on a host of other illnesses, and more headlines are sure to appear.

Related searches

Helen Mayberg (the speaker at APA)

Brodmann area 25 (the affected cortical region).

Evidence-based Articles

Ponder this: A recent meta-analysis by Johns Hopkins researchers finds a “high rate of suicide” among Parkinson’s patients treated with DBS.
You have the option to purchase full text by clicking the link “View Medline

Clinical Trials

You can learn from information about clinical trials where the procedure is being tested.


Eluting stents cleared of death charge

July 8, 2008

Medicare claims show no added mortality risk from drug-eluting stents

Doctors at Dartmouth compared outcomes for people who had metal stents before the sirolimus-eluting stent became available with those for who later got the new stent called Cypher. There was virtually no difference in mortality, they report in the Journal of the American Medical Association.

As in prior studies, those who had the drug-eluting stent were less likely to need treatment for restenosis.

The drug-eluting stent certainly does no harm, conclude the authors, who compared data from nearly 67,000 individuals given stents on a non-emergency basis.

But they didn’t study the paclitaxel-eluting stent (Taxus) and could not assess the possible influence of dual-antiplatelet therapy.

Related searches

STEMI stents

Taxus

Evidence-based Articles

What is the existing evidence about the best protocol for dual antiplatelet therapy in patients who are stented?

Research/Reviews

What is the risk of late thrombosis in stent recipients?

Practice Guidelines

What are current practice standards in use of drug-eluting stents?


When enough is too much

July 8, 2008

New success measures for late-stage cancer treatment evoke tough questions

Among 11 candidate biomarkers under study in the UK MRC FOCUS trial, the largest-yet trial of metastatic colorectal cancer, levels of topoisomerase-1 (Topo1) appears to be the only one that predicts response to irinotecan in combination with fluorouracil. Patients with a high response to Topo1 gained a median 5.3 months of survival.

In the other arm of the trial, Topo1’s predictive value for fluoruracil-oxaliplatin was suggestive but not significant, at p = 0.05.

Oncologists have been wondering aloud how to communicate with patients when (as in the study above), continuing chemotherapy offers only a few more months of life at the cost of adverse effects.

“When is enough enough?” ask the authors of an article in a recent issue of the Journal of the American Medical Association

Another recent report, this one in the Journal of Clinical Oncology,assesses prognostic factors for 2-month survival among hospitalized patients with advanced solid tumors. A combination of factors proved most predictive:

* Karnofsky index
* Number of metastatic sites
* Low serum albumin, and
* LDH concentration

The patient’s desire to continue treatment was also associated with survival.

Evidence-based Articles

A recent article in BMJ Clinical Evidence by authors from the UK and Canada ponders whether adverse effects data from major trials like the one above can be relevant in community practice, and how to make them more so.

Related searches

topoisomerase-1 irinotecan

chemotherapy decision aids